Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2013 - 2026)

Sarepta Therapeutics' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $136.4 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 58.04% year-over-year to $136.4 million in Q1 2026; TTM through Mar 2026 was $136.4 million, a 58.04% decrease from a year earlier, with the FY2025 full-year figure at $83.9 million, down 74.18% from the prior year.
• Non-Current Deffered Revenue climbed to $136.4 million in Q1 2026 per SRPT's latest filing, from $83.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $552.2 million in Q1 2022 and bottomed at $83.9 million in Q4 2025.
• The 5-year median for Non-Current Deffered Revenue is $437.0 million (2023), against an average of $387.5 million.
• Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2025; the steepest drop was 74.18% in 2025.
• Year by year, Non-Current Deffered Revenue stood at $485.0 million in 2022, then fell by 9.9% to $437.0 million in 2023, then dropped by 25.63% to $325.0 million in 2024, then sank by 74.18% to $83.9 million in 2025, then soared by 62.5% to $136.4 million in 2026.
• Per Business Quant, the three latest SRPT Non-Current Deffered Revenue figures stand at $136.4 million (Q1 2026), $83.9 million (Q4 2025), and $325.0 million (Q1 2025).